Verrica Pharmaceuticals
VRCA
58 hedge funds and large institutions have $13.4M invested in Verrica Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 30 closing their positions.
3% more capital invested
Capital invested by funds: $13M → $13.4M (+$396K)
0.52% less ownership
Funds ownership: 3.21% → 2.69% (-0.52%)
22% less funds holding
Funds holding: 74 → 58 (-16)
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
53% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$275K |
| 2 |
SA
Sovran Advisors
San Diego,
California
|
+$193K |
| 3 |
AC
Armistice Capital
New York
|
+$169K |
| 4 |
CP
Caligan Partners
New York
|
+$132K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$1.24M |
| 2 |
BlackRock
New York
|
-$630K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$386K |
| 4 |
State Street
Boston,
Massachusetts
|
-$256K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$200K |
VRCA Hedge Fund Activity: Q2 2025 in Review
58 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2025, worth a combined $13.4M — up 3% from $13M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of VRCA and 14 opened new positions — a net loss of 16 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, adding an estimated $275K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $1.24M sold.
- 58 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2025, down from 74 in Q1 2025.
- Funds reported $13.4M of Verrica Pharmaceuticals stock for Q2 2025, up 3% quarter-over-quarter.
- 14 funds opened new Verrica Pharmaceuticals positions in Q2 2025 and 30 closed out, a net change of -16 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $275K added.
- The largest Verrica Pharmaceuticals seller in Q2 2025 was Boothbay Fund Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2025.